Document:

<PAGE>
                                                                   Exhibit 10.22

[*] CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
    BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
    EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES EXCHANGE ACT OF
    1933, AS AMENDED.

[CYTOKINETICS LOGO]                        280 East Grand Avenue
                                           South San Francisco, CA 94080
                                           Tel (650) 624-3000 Fax (650) 624-3010

July 11, 2003

Glaxo Group Limited, doing business as GlaxoSmithKline
709 Swedeland Road
King of Prussia, Pennsylvania 19406
Attn: Pradip K. Bhatnagar, Ph.D., Director, Genetic & Discovery Alliances

RE: ASSIGNMENT OF GSK MEDICINAL CHEMISTRY PERSONNEL TO HIT-TO-LEAD ACTIVITIES
UNDER THAT CERTAIN COLLABORATION AND LICENSE AGREEMENT BY AND BETWEEN GLAXO
GROUP LIMITED, A GLAXOSMITHKLINE COMPANY, ("GSK") AND CYTOKINETICS, INC. ("CK")
OF EVEN DATE JUNE 20, 2001 (THE "COLLABORATION AGREEMENT")

Dear Pradip:

Pursuant to that certain letter amendment to the Collaboration Agreement of even
date November 5, 2002 (the "Letter Amendment"), GSK and CK agreed to amend the
Collaboration Agreement in order to allow GSK to assign certain medicinal
chemistry personnel within GSK to perform hit-to-lead activities as part of the
Research Program under the Collaboration Agreement without such assignment
accruing toward the [*] ([*]) FTE limit of establishing a [*] Program pursuant
to Section 2.6.2(a) of the Collaboration Agreement.

Pursuant to this letter amendment to the Collaboration Agreement (the "H2L
Letter Amendment"), GSK and CK desire to void such Letter Amendment in its
entirety and replace it with this H2L Letter Amendment, all on the terms set
forth herein.

Now therefore, GSK and CK agree, effective as of November 5, 2002 (the "H2L
Letter Amendment Effective Date"), as follows:

     1.   All capitalized terms not defined herein shall have the meaning
          ascribed to them in the Collaboration Agreement.

     2.   The Letter Amendment shall be void and have no force or effect as
          between the parties, effective November 5, 2002.

     3.   GSK may assign chemistry personnel (other than CK FTEs) within GSK's
          chemistry resource at the rate (i.e., a running rate) of [*] ([*])
          full-time equivalents or more, solely to perform Hit-To-Lead
          activities under the Research Program relating to a particular Mitotic
          Kinesin Target, without such assignment and Hit-To-Lead activities
          accruing toward the [*]([*]) FTE limit of establishing a [*] Program
          pursuant to Section 2.6.2(a).

* Certain information on this page has been omitted and filed separately with
  the Commission. Confidential treatment has been requested with respect to the
  omitted portions.
<PAGE>
Pradip K. Bhatnagar, Ph.D.
July 11, 2003
Page Two

     4.   Notwithstanding the foregoing, if a Tractable Compound has been
          identified with respect to a particular Mitotic Kinesin Target, the
          assignment by GSK of any chemistry personnel (other than CK FTEs) to
          perform activities relating to such Mitotic Kinesin Target, including
          without limitation any chemistry personnel within GSK's
          high-throughout chemistry resource (the "HTC Resource") and regardless
          of the activities of such personnel, shall accrue towards the [*]([*])
          FTE limit of establishing a [*] Program pursuant to Section 2.6.2(a).

     5.   As used herein, "Hit-To-Lead" shall mean those activities directed to
          the process of synthesizing and identifying active new chemical
          entities up to and including identification of a compound that meets
          the Tractable Compound Criteria. It is understood that activities
          directed to the subsequent synthetic modification and testing of a
          Tractable Compound are not included in Hit-To-Lead.

     6.   Except as specifically modified or amended hereby, the Collaboration
          Agreement shall remain in full force and effect and, as modified or
          amended, is hereby ratified, confirmed and approved. No provision of
          this H2L Letter Amendment may be modified or amended except expressly
          in a writing signed by both parties nor shall any terms be waived
          except expressly in a writing signed by the party charged therewith.
          This H2L Letter Amendment shall be governed in accordance with the
          laws of the State of New York, without regard to principles of
          conflicts of laws.

Please sign and return two copies of this letter if you agree to the foregoing
terms.

Sincerely,

/s/ Robert I. Blum

Robert I. Blum
Senior Vice President, Finance and Corporate Development
Chief Financial Officer
Cytokinetics, Inc.

Agreed and accepted:

GLAXO GROUP LIMITED

      /s/ Pradip Bhatnagar
------------------------------------

Name: Pradip Bhatnagar
     -------------------------------

Title: Director, Alliance Management
      ------------------------------

cc:  Vice President, Business Development, Glaxo Group Limited, doing business
     as GlaxoSmithKline
     Senior Vice President and Assistant General Counsel-R&D Legal Operations,
     GlaxoSmithKline Corporate Legal Department
     Kenneth A. Clark, Esq., Wilson Sonsini Goodrich & Rosati Professional
     Corporation

*    Certain information on this page has been omitted and filed separately with
     the Commission. Confidential treatment has been requested with respect to
     the omitted portions.<PAGE>
                                                             Exhibit 10.23

[*] CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
    BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
    EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES EXCHANGE ACT OF
    1933, AS AMENDED.

[CYTOKINETICS LOGO]                   280 East Grand Avenue
                                      South San Francisco, CA 94080
                                      Tel (650) 624-3000 Fax (630) 624-3010

July 28, 2003

Glaxo Group Limited, doing business as GlaxoSmithKline
709 Swedeland Road
King of Prussia, Pennsylvania 19406
Attn: Pradip K. Bhatnagar, Ph.D., Director, Genetic & Discovery Alliances

RE: COMPOUND CRITERIA UNDER THAT CERTAIN COLLABORATION AND LICENSE AGREEMENT BY
AND BETWEEN GLAXO GROUP LIMITED, A GLAXOSMITHKLINE COMPANY, ("GSK") AND
CYTOKINETICS, INC. ("CK") OF EVEN DATE JUNE 20, 2001 (THE "COLLABORATION
AGREEMENT").

Dear Pradip:

Pursuant to this letter amendment to the Collaboration Agreement (the "Compound
Criteria Letter Amendment"), GSK and CK desire to revise the Compound Criteria
applicable under the Collaboration Agreement as approved by the JRC on
September 21, 2001, all on the terms set forth herein.

Now therefore, GSK and CK agree as follows:

     1.   All capitalized terms not defined herein shall have the meaning
          ascribed to them in the Collaboration Agreement.

     2.   For purposes of the Collaboration Agreement, "Compound Criteria" shall
          mean, effective as of the Effective Date, those criteria set forth in
          the revised Exhibit 1.17 attached hereto and incorporated by
          reference. For clarity, it is understood that the Compound Criteria
          may only be modified or amended pursuant in a writing signed by both
          Parties referencing the Collaboration Agreement and expressly
          modifying or amending the Compound Criteria.

     3.   Except as specifically modified or amended hereby, the Collaboration
          Agreement shall remain in full force and effect and, as modified or
          amended, is hereby ratified, confirmed and approved. No provision of
          this Compound Criteria Letter Amendment may be modified or amended
          except expressly in a writing signed by both Parties nor shall any
          terms be waived except expressly in a writing signed by the Party
          charged therewith. This Compound Criteria Letter Amendment shall be
          governed in accordance with the laws of the State of New York, without
          regard to principles of conflicts of laws.

* Certain information on this page has been omitted and filed separately with
  the Commission. Confidential treatment has been requested with respect to the
  omitted portions.

<PAGE>

Pradip K. Bhatnagar, Ph.D.
July 28, 2003
Page Two

Please sign and return two copies of this letter if you agree to the foregoing
terms.

Sincerely,

/s/ Robert I. Blum
-------------------------
Robert I. Blum
Senior Vice President, Finance and Corporate Development
Chief Financial Officer
Cytokinetics, Inc.

Agreed and accepted:

GLAXO GROUP LIMITED

/s/ Pradip K. Bhatnagar
--------------------------

Name: Pradip K. Bhatnagar

Title: Director

cc: Vice President, Business Development, Glaxo Group Limited, doing
    business as GlaxoSmithKline
    Senior Vice President and Assistant General Counsel-R&D Legal Operations,
    GlaxoSmithKline Corporate Legal Department
    Kenneth A. Clark, Esq., Wilson Sonsini Goodrich & Rosati Professional
    Corporation

<PAGE>
                                  EXHIBIT 1.17
                          [Revised September 21, 2001]

                               Compound Criteria
                        (effective as of June 20, 2001)

[*]

* Certain information on this page has been omitted and filed separately with
  the Commission. Confidential treatment has been requested with respect to the
  omitted portions.<PAGE>
                                                                   Exhibit 10.24

[*] CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
    BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
    EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES EXCHANGE ACT OF
    1933, AS AMENDED.

[CYTOKINETICS LOGO]                        280 East Grand Avenue
                                           South San Francisco, CA 94080
                                           Tel (650) 624-3000 Fax (650) 624-3010

July 28, 2003

Glaxo Group Limited, doing business as GlaxoSmithKline
709 Swedeland Road
King of Prussia, Pennsylvania 19406
Attn: Pradip K. Bhatnagar, Ph.D., Director, Genetic & Discovery Alliances

RE: FEASIBILITY STUDY UNDER THAT CERTAIN COLLABORATION AND LICENSE AGREEMENT BY
AND BETWEEN GLAXO GROUP LIMITED, A GLAXOSMITHKLINE COMPANY, ("GSK") AND
CYTOKINETICS, INC. ("CK") OF EVEN DATE JUNE 20, 2001 (THE "COLLABORATION
AGREEMENT")

Dear Pradip:

Pursuant to this letter amendment to the Collaboration Agreement (the
"Feasibility Study Letter Amendment"), GSK and CK desire to revise the
definition of Feasibility Study applicable under the Collaboration Agreement as
agreed by the JRC on July 25, 2003, all on the terms set forth herein.

Now therefore, GSK and CK agree as follows:

1.  All capitalized terms not defined herein shall have the meaning ascribed to
    them in the Collaboration Agreement.

2.  For purposes of the Collaboration Agreement, "Feasibility Study" shall have
    the meaning, effective as of the Effective Date, set forth in the revised
    Exhibit 6.3.2, attached hereto and incorporated herein. For clarity, it is
    understood that the definition of Feasibility Study may only be modified or
    amended pursuant in a writing signed by both Parties referencing the
    Collaboration Agreement and expressly modifying or amending the definition
    of Feasibility Study.

3.  Except as specifically modified or amended hereby, the Collaboration
    Agreement shall remain in full force and effect and, as modified or amended,
    is hereby ratified, confirmed and approved. No provision of this Feasibility
    Study Letter Amendment may be modified or amended except expressly in a
    writing signed by both Parties nor shall any terms be waived except
    expressly in a writing signed by the Party charged therewith. This
    Feasibility Study Letter Amendment shall be governed in accordance with the
    laws of the State of New York, without regard to principles of conflicts of
    laws.

* Certain information on this page has been omitted and filed separately with
  the Commission. Confidential treatment has been requested with respect to the
  omitted portions.
<PAGE>
Pradip K. Bhatnagar, Ph.D.
July 28, 2003
Page Two

Please sign and return two copies of this letter if you agree to the foregoing
terms.

Sincerely,

/s/ Robert I. Blum
---------------------------
Robert I. Blum
Senior Vice President, Finance and Corporate Development
Chief Financial Officer
Cytokinetics, Inc.

Agreed and accepted:

GLAXO GROUP LIMITED

/s/ Pradip K. Bhatnagar
--------------------------

Name: Pradip K. Bhatnagar
      --------------------

Title: Director
       -------------------

cc:  Vice President, Business Development, Glaxo Group Limited, doing business
     as GlaxoSmithKline
     Senior Vice President and Assistant General Counsel-R&D Legal Operations,
     GlaxoSmithKline Corporate Legal Department
     Kenneth A. Clark, Esq., Wilson Sonsini Goodrich & Rosati Professional
     Corporation
<PAGE>
                                 EXHIBIT 6.3.2
                            [Revised July 25, 2003]

                               Feasibility Study
                        (effective as of June 20, 2001)

                                      [*]

* Certain information on this page has been omitted and filed separately with
  the Commission. Confidential treatment has been requested with respect to the
  omitted portions.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00065-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00065-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00065-of-00352.parquet"}]]